Real-world-study-comparing-NOACs-in-AF-patients
Independent large real-world study comparing NOACs in AF-patientsA recently published large retrospective comparative study investigated stroke, bleeding and mortality risks in older US Medicare patients treated with commonly marketed oral anticoagulants for non-valvular atrial fibrillation1 Results of the real-world study showed that Pradaxa ® (dabigatran etexilate) was associated with a more favourable benefit-risk profile in comparison to both warfarin and rivaroxaban1Data from an earlier FDA-funded Medicare study published in 2015, which investigated cardiovascular, bleeding and mortality risks among patients treate...
Source: Boehringer Ingelheim Corporate News - April 15, 2019 Category: Research Source Type: news
Doctors: Newer Blood Thinners Best Against A-Fib
The newer drugs are called non-vitamin K oral anticoagulants (NOACs). Examples include dabigatran (Pradaxa), rivaroxaban (Xarelto) and apixaban (Eliquis). (Source: WebMD Health)
Source: WebMD Health - January 28, 2019 Category: Consumer Health News Source Type: news
Dabigatran, Rivaroxaban, Warfarin in Oldest Adults With AF Dabigatran, Rivaroxaban, Warfarin in Oldest Adults With AF
This study compared the effectiveness and safety of reduced-dose dabigatran, reduced-dose rivaroxaban, and warfarin in individuals aged 85 and older with atrial fibrillation.Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 1, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
HeartMate 3 OK'd for Destination Tx; Pradaxa Flops in ESUS; Heater-Cooler Infection
(MedPage Today) -- Recent developments of interest in cardiovascular medicine (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - October 22, 2018 Category: Cardiology Source Type: news
NOACs for Mechanical Heart Valves: Is the Door Still Open? NOACs for Mechanical Heart Valves: Is the Door Still Open?
Currently, NOACs are contraindicated in patients with mechanical heart valves based on the results of a single study comparing dabigatran and warfarin. Does this need to be re-evaluated?Circulation (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 22, 2018 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news
Results from two Pradaxa trials to be presented at WSC
Results from Pradaxa ® RE-SPECT ESUS® and RE-SPECT CVT® trials to be presented at the 11th World Stroke CongressData from key trials will aid in increasing scientific understanding of ESUS and CVTRESPECT-ESUS is first randomised trial to investigate clinical profile of Pradaxa ® vs ASA (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - October 12, 2018 Category: Research Source Type: news
New data at ESC supports Pradaxa safety profile
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - August 16, 2018 Category: Research Source Type: news
Real-World MI Risk Lower With NOACs vs Warfarin in AFib Real-World MI Risk Lower With NOACs vs Warfarin in AFib
The results, from a large registry, add to a growing body of evidence supporting the general safety of direct oral anticoagulants and may finally put to rest concerns about an MI signal with dabigatran.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 29, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
Boehringer Ingelheim taps Medisafe for bundled Pradaxa offering
Medication management and adherence app maker Medisafe has announced a partnership with Boehringer Ingelheim following a successful pilot.
Medisafe will offer a wraparound app experience that incorporates Pradaxa-specific educational information into a special version of its app, which patients will be directed to when they ' re prescribed the drug. (Source: mobihealthnews)
Source: mobihealthnews - June 22, 2018 Category: Information Technology Source Type: news
Encouraging Early Safety Data for Dabigatran in Stroke Encouraging Early Safety Data for Dabigatran in Stroke
Results of a preliminary study show no increase in symptomatic hemorrhagic transformation with dabigatran vs aspirin in patients with TIA or minor stroke.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - May 30, 2018 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
Vibrating ICD/CRT-D; Pradaxa Reversal Agent; Prevention Bonanza
(MedPage Today) -- Recent developments of interest in cardiovascular medicine (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 23, 2018 Category: Urology & Nephrology Source Type: news
Dabigatran Antidote Praxbind Picks Up Full FDA Approval Dabigatran Antidote Praxbind Picks Up Full FDA Approval
Granted accelerated approval in 2015, the company now has received full FDA approval for idarucizumab to reverse the effects of dabigatran.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 18, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news
FDA Provides Full Approval to Praxbind (idarucizumab), Specific Reversal Agent for Pradaxa
Ridgefield, Conn., April 17, 2018 – Boehringer Ingelheim today announced that the U.S. Food and Drug Administration (FDA) has provided full approval for Praxbind (idarucizumab), the specific reversal agent for Pradaxa (dabigatran etexilate... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - April 17, 2018 Category: Drugs & Pharmacology Source Type: news
Fewer Events on Dabigatran After Post-Noncardiac Surgery MI Fewer Events on Dabigatran After Post-Noncardiac Surgery MI
In the MANAGE trial, long-term dabigatran seemed protective in patients with the syndrome of myocardial injury after noncardiac surgery (MINS); observers debated just how to respond to the study.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - March 23, 2018 Category: Surgery Tags: Cardiology News Source Type: news
Another Way to Save a Life: the MANAGE Trial Another Way to Save a Life: the MANAGE Trial
Dr Walton-Shirley was impressed by a study on dabigatran for myocardial injury after noncardiac surgery at the American College of Cardiology Annual Scientific Session.theheart.org on Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 12, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news
